Blackstone Inc’s Maze Therapeutics MAZE Stock Holding History

Blackstone Inc’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-24,990	Closed	-$746K	–	694
2026 Q1	$746K	Buy	+24,990	New	+$1.1M	﹤0.01%	264

Other funds holding MAZE

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Blackstone Inc's MAZE Position: Q2 2026 in Review

Blackstone Inc sold out of Maze Therapeutics (MAZE) in Q2 2026, closing a stake of 24,990 shares — an estimated $746K sold.

Blackstone Inc first reported a position in MAZE in Q1 2026 and held it in 1 quarter. The position peaked at $746K in Q1 2026. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

Blackstone Inc reported no remaining Maze Therapeutics position as of Q2 2026 after selling out during the quarter.
Blackstone Inc sold 24,990 Maze Therapeutics shares in Q2 2026, an estimated $746K.
Blackstone Inc first reported a position in Maze Therapeutics in Q1 2026 and held it in 1 quarter.
Blackstone Inc's Maze Therapeutics position peaked at $746K in Q1 2026.
162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Blackstone Inc's 13F filing for Q2 2026, filed 14 Aug 2026.